P38 MAPK alpha mediates cytokine-induced IL-6 and MMP-3 expression in human cardiac fibroblasts

Biochemical and Biophysical Research Communications

Volumn 430, Issue 1, 2013, Pages 419-424

  Sinfield, John K ^a,b   Das, Anupam ^a,b   O'Regan, David J ^b,c   Ball, Stephen G ^a,b   Porter, Karen E ^a,b   Turner, Neil A ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Cardiac fibroblasts; Heart; Interleukin; Matrix metalloproteinase; P38 MAPK

Indexed keywords

INTERLEUKIN 1ALPHA; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 14; PROTEIN P38 DELTA; PROTEIN P38 GAMMA; SMALL INTERFERING RNA; STROMELYSIN; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CARDIAC FIBROBLAST; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; QUALITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELLS, CULTURED; FIBROBLASTS; HUMANS; INTERLEUKIN-1ALPHA; INTERLEUKIN-6; MATRIX METALLOPROTEINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE 14; MYOCARDIUM;

EID: 84872390677     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.11.071     Document Type: Article

References (34)

1. Porter K.E., Turner N.A. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol. Ther. 2009, 123:255-278.
2. Frangogiannis N.G., Smith C.W., Entman M.L. The inflammatory response in myocardial infarction. Cardiovasc. Res. 2002, 53:31-47.
3. Frangogiannis N.G., Entman M.L. Chemokines in myocardial ischemia. Trends Cardiovasc. Med. 2005, 15:163-169.
4. van den Borne S.W., Diez J., Blankesteijn W.M., Verjans J., Hofstra L., Narula J. Myocardial remodeling after infarction: the role of myofibroblasts. Nat. Rev. Cardiol. 2010, 7:30-37.
5. Turner N.A., Das A., Warburton P., O'Regan D.J., Ball S.G., Porter K.E. Interleukin-1α stimulates pro-inflammatory cytokine expression in human cardiac myofibroblasts. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H1117-H1127.
6. Turner N.A., Das A., O'Regan D.J., Ball S.G., Porter K.E. Human cardiac fibroblasts express ICAM-1, E-selectin and CXC chemokines in response to proinflammatory cytokine stimulation. Int. J. Biochem. Cell Biol. 2011, 43:1450-1458.
7. Turner N.A., Porter K.E. Regulation of myocardial matrix metalloproteinase expression and activity by cardiac fibroblasts. IUBMB Life 2012, 64:143-150.
8. Turner N.A., Warburton P., O'Regan D.J., Ball S.G., Porter K.E. Modulatory effect of interleukin-1α on expression of structural matrix proteins, MMPs and TIMPs in human cardiac myofibroblasts: role of p38 MAP kinase. Matrix Biol. 2010, 29:613-620.
9. Melendez G.C., McLarty J.L., Levick S.P., Du Y., Janicki J.S., Brower G.L. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 2010, 56:225-231.
10. Mukherjee R., Bruce J.A., McClister D.M., Allen C.M., Sweterlitsch S.E., Saul J.P. Time-dependent changes in myocardial structure following discrete injury in mice deficient of matrix metalloproteinase-3. J. Mol. Cell. Cardiol. 2005, 39:259-268.
11. Clark J.E., Sarafraz N., Marber M.S. Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease. Pharmacol. Ther. 2007, 116:192-206.
12. Aukrust P., Gullestad L., Ueland T., Damas J.K., Yndestad A. Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications. Ann. Med. 2005, 37:74-85.
13. Kyriakis J.M., Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 2001, 81:807-869.
14. Turner N.A. Therapeutic regulation of cardiac fibroblast function: targeting stress-activated protein kinase pathways. Fut. Cardiol. 2011, 7:673-691.
15. Yeh C.C., Li H., Malhotra D., Turcato S., Nicholas S., Tu R., Zhu B.Q., Cha J., Swigart P.M., Myagmar B.E., Baker A.J., Simpson P.C., Mann M.J. Distinctive ERK and p38 signaling in remote and infarcted myocardium during post-MI remodeling in the mouse. J. Cell. Biochem. 2010, 109:1185-1191.
16. Porter K.E., Turner N.A., O'Regan D.J., Balmforth A.J., Ball S.G. Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Cardiovasc. Res. 2004, 61:745-755.
17. 2-adrenergic receptor stimulation increases proliferation of human cardiac fibroblasts via an autocrine mechanism. Cardiovasc. Res. 2003, 57:784-792.
18. Mughal R.S., Warburton P., O'Regan D.J., Ball S.G., Turner N.A., Porter K.E. Peroxisome proliferator-activated receptor γ-independent effects of thiazolidinediones on human cardiac myofibroblast function. Clin. Exp. Pharmacol. Physiol. 2009, 36:478-486.
19. 1A receptor internalisation. Cell. Signalling 2001, 13:269-277.
20. 2+ signaling in human venous endothelial cells. Multiple roles for reactive oxygen species. J. Biol. Chem. 2005, 280:13349-13354.
21. Turner N.A., Mughal R.S., Warburton P., O'Regan D.J., Ball S.G., Porter K.E. Mechanism of TNFα-induced IL-1α, IL-1β and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones. Cardiovasc. Res. 2007, 76:81-90.
22. Porter K.E., Turner N.A., O'Regan D.J., Ball S.G. Tumor necrosis factor α induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Cardiovasc. Res. 2004, 64:507-515.
23. Lemke L.E., Bloem L.J., Fouts R., Esterman M., Sandusky G., Vlahos C.J. Decreased p38 MAPK activity in end-stage failing human myocardium: p38 MAPKα is the predominant isoform expressed in human heart. J. Mol. Cell. Cardiol. 2001, 33:1527-1540.
24. Dingar D., Merlen C., Grandy S., Gillis M.A., Villeneuve L.R., Mamarbachi A.M., Fiset C., Allen B.G. Effect of pressure overload-induced hypertrophy on the expression and localization of p38 MAP kinase isoforms in the mouse heart. Cell. Signalling 2010, 22:1634-1644.
25. Court N.W., dos Remedios C.G., Cordell J., Bogoyevitch M.A. Cardiac expression and subcellular localization of the p38 mitogen-activated protein kinase member stress-activated protein kinase-3 (SAPK3). J. Mol. Cell. Cardiol. 2002, 34:413-426.
26. 2B receptors induces interleukin-6 secretion in cardiac fibroblasts via the PKC-δ-P38 signaling pathway. Br. J. Pharmacol. 2010, 159:1598-1607.
27. Tenhunen O., Rysa J., Ilves M., Soini Y., Ruskoaho H., Leskinen H. Identification of cell cycle regulatory and inflammatory genes as predominant targets of p38 mitogen-activated protein kinase in the heart. Circ. Res. 2006, 99:485-493.
28. Brown R.D., Jones G.M., Laird R.E., Hudson P., Long C.S. Cytokines regulate matrix metalloproteinases and migration in cardiac fibroblasts. Biochem. Biophys. Res. Commun. 2007, 362:200-205.
29. Evans I.M., Britton G., Zachary I.C. Vascular endothelial growth factor induces heat shock protein (HSP) 27 serine 82 phosphorylation and endothelial tubulogenesis via protein kinase D and independent of p38 kinase. Cell. Signalling 2008, 20:1375-1384.
30. Mudgett J.S., Ding J., Guh-Siesel L., Chartrain N.A., Yang L., Gopal S., Shen M.M. Essential role for p38α mitogen-activated protein kinase in placental angiogenesis. Proc. Natl. Acad. Sci. USA 2000, 97:10454-10459.
31. Sudo T., Kawai K., Matsuzaki H., Osada H. P38 mitogen-activated protein kinase plays a key role in regulating MAPKAPK2 expression. Biochem. Biophys. Res. Commun. 2005, 337:415-421.
32. Kotlyarov A., Yannoni Y., Fritz S., Laass K., Telliez J.B., Pitman D., Lin L.L., Gaestel M. Distinct cellular functions of MK2. Mol. Cell. Biol. 2002, 22:4827-4835.
33. Cohen P. Targeting protein kinases for the development of anti-inflammatory drugs. Curr. Opin. Cell Biol. 2009, 21:317-324.
34. Marber M.S., Rose B., Wang Y. The p38 mitogen-activated protein kinase pathway-A potential target for intervention in infarction, hypertrophy, and heart failure. J. Mol. Cell. Cardiol. 2011, 51:485-490.